1
|
Ozdemir CY, Arioz DT, Celik F, Cicekli N, Chkhikvadze M, Bilir F, Yılmaz S, Vatansever N. The Role of Lymphovascular Space Invasion and Cytology in the Prognosis of Endometrial Cancer. Discov Med 2024; 36:366-371. [PMID: 38409841 DOI: 10.24976/discov.med.202436181.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/28/2024]
Abstract
BACKGROUND Lymphovascular space invasion (LVSI) and cytology are both independent and strong prognostic factors in endometrial cancer. This study aims to highlight the impact of LVSI and cytology positivity on prognosis, in addition to molecular classification. METHODS A retrospective review was conducted on the records of 223 patients with endometrial cancer diagnosed between January 2011 and January 2021. The inclusion criteria stipulated that the patients were diagnosed with endometrial cancer by endometrial biopsy and were operated in the clinic. The exclusion criteria included sarcoma in the postoperative pathology report results or synchronous tumor. Staging was performed according to the Fédération internationale de gynécologie et d'obstétrique (FIGO) 2009 criteria. Cytology (using 50 cc saline) was obtained upon entry into the peritoneal cavity. In 20 patients, saline was not used due to the presence of ascites in the abdomen. The Kaplan-Meier method was employed to evaluate overall survival and progression-free survival. Survival rates were compared in terms of cytology and LVSI. RESULTS After analyzing the postoperative pathology results, it was found that the mean tumor size was 4.03 ± 2.3 cm. The most common histological type was endometrioid carcinoma, with stage IA being the most common stage. Out of 223 patients with endometrial cancer, the overall survival rate was 82.4%, and the progression-free survival rate was 88.3%. For patients negative for LVSI, the progression-free survival rate was 93%, while for LVSI-positive patients, it was 77.3% (p < 0.001). Additionally, the progression-free survival rate for patients negative for cytology was 90.4%, whereas for cytology-positive patients, it was 77.1% (p < 0.05). CONCLUSIONS In our study, we observed that LVSI positivity and cytology positivity also reduced the overall survival rate. We aimed to highlight that, in addition to molecular classification, cytology positivity and LVSI positivity are still highly significant and independent factors in prognosis.
Collapse
Affiliation(s)
- Cem Yagmur Ozdemir
- Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of Gynecological Oncology, 03030 Afyonkarahisar, Turkey
| | - Dagistan Tolga Arioz
- Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of Gynecological Oncology, 03030 Afyonkarahisar, Turkey
| | - Fatih Celik
- Afyonkarahisar Health Sciences University Hospital, Facutly of Medicine, Department of Obstetrics and Gynecology, 03030 Afyonkarahisar, Turkey
| | - Nayif Cicekli
- Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of Gynecological Oncology, 03030 Afyonkarahisar, Turkey
| | - Mariam Chkhikvadze
- American Hospital Tbilisi, Department of Obstetrics and Gynecology, 0144 Tbilisi, Georgia
| | - Filiz Bilir
- Zeynep Kamil Women and Children Diseases Traning and Research Hospital, Department of Gynecological Oncology, 34668 Istanbul, Turkey
| | - Sezgin Yılmaz
- Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of General Surgery, 03030 Afyonkarahisar, Turkey
| | - Nefize Vatansever
- Izmir Cigli Regional Training and Research Hospital, Department of Gynecological Oncology, 35620 Izmir, Turkey
| |
Collapse
|
2
|
Bilir F, Arıoz DT, Arıkan SE, Yalcın GS, Ozdemir C, Demir H, Chkhikvadze M, Ozdemir CY, Cicekli N, Vatansever N, Yılmaz S. Relationship between molecular markers and lymphadenectomy and lymphovascular space invasion in endometrial cancer. Arch Gynecol Obstet 2023; 308:941-946. [PMID: 36959366 DOI: 10.1007/s00404-023-07005-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Accepted: 03/05/2023] [Indexed: 03/25/2023]
Abstract
PURPOSE Relationship between pathologic parameters, surgical parameters, or lymph node status with oncologic outcomes is not fully elucidated in endometrial cancer (EC). We want to investigate the molecular classification of uterine cancer in the Turkish population and its relationship between lymphadenectomy and lymph node metastasis. METHODS In this study, 100 patients' clinical and pathologic data diagnosed with EC were analyzed. Pathologic and molecular parameters were investigated and compared them with clinical parameters. RESULTS According to the molecular analysis, 16 patients (16%) had p53 mutation, 3 patients (3%) were classified as POLE mutant group, 38 (38%) patients in the MSI group, and the remaining 43 patients (43%) into the no specific mutation profile (NSMP) group. Lymph node metastasis rate was significantly higher in copy number high (CNH) group compared to the others. In the CNH group, 29 of 437 (6.6%) dissected lymph nodes had metastasis. The median OS was the highest in the POLE group (72 months) and lowest in the CNH group (36 months). CONCLUSION Endometrial cancer patients showed significantly different overall and disease-free survival according to the molecular subtypes and it was consistent with the literature, Lymph node metastasis risk was the highest in CNH group. MSI status is important for the lymph node metastasis risk but not all abnormalities, especially PMS2 and MLH1 expression changes showed the highest risk.
Collapse
Affiliation(s)
- Filiz Bilir
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey.
- Cumhuriyet Mh Oren Sk Modul Sitesi A21 Kartal, Istanbul, Turkey.
| | - Dagıstan Tolga Arıoz
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Suna Evrim Arıkan
- Department of Medical Biology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Gulsum Seyma Yalcın
- Department of Pathology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Cigdem Ozdemir
- Department of Pathology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Hacer Demir
- Department of Medical Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Mariam Chkhikvadze
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Cem Yagmur Ozdemir
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Nayif Cicekli
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Nefize Vatansever
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Sezgin Yılmaz
- Department of General Surgery, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| |
Collapse
|
3
|
Çakır E, Saydan D, Gülbagcı B, Özen M, Uğurlu I, Demirci A, Bilir F, Hacıbekiroglu I, Yıldız N, Akcali S, Altindis M, Varım C, Yaylaci S, Bilir C. Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment. Eur Rev Med Pharmacol Sci 2023; 27:4309-4315. [PMID: 37203857 DOI: 10.26355/eurrev_202305_32341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
OBJECTIVE Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. Most of the studies in the literature compared the immunity in cancer patients with a cross-sectional cohort or retrospectively. Our study investigated Sinovac-CoronaVac COVID-19 vaccine immunogenicity and compared it with natural COVID-19 disease in cancer patients during their cancer therapy. PATIENTS AND METHODS A total of 111 patients with cancer and who are on active treatment were included in the study. This is a single-center study and was designed prospectively. Two group of patients were included in the study, natural disease and vaccinated group. RESULTS A total of 111 patients were included in the study, 34 of whom had natural COVID-19 disease. Antibody levels following the first dose vaccine were 0.4 (0-1.9) U/ml while after the second dose of vaccine were 2.6 (1.0-7.25) U/ml. Immunogenicity levels were 82.4% in the natural disease group and 75.8% in the vaccinated group after the second shot of the vaccine. Immunogenicity rate was significantly higher in non-chemotherapy (receiving immunotehrapy/targeted therapy or biologic agent) group compared to chemotherapy drug (92.9% vs. 63.3%, p=0.004). There was a difference between the antibody levels following the first and second vaccination [median (IQR): 0.3 (0-1.0) and 3.3 (2.0-6.7), p=0.001, respectively]. CONCLUSIONS The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving active systemic therapy. On the other hand, natural disease immunogenicity was higher than vaccinated group.
Collapse
Affiliation(s)
- E Çakır
- Department of Medical Oncology, Medicine Faculty, Sakarya University, Sakarya, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Yıldız SZ, Bilir C, Eskiler GG, Bilir F. The Anticancer Potential of Chlorine Dioxide in Small-Cell Lung Cancer Cells. Cureus 2022; 14:e29989. [PMID: 36381770 PMCID: PMC9636887 DOI: 10.7759/cureus.29989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/06/2022] [Indexed: 11/06/2022] Open
Abstract
Background Chlorine dioxide (ClO2) is an effective disinfectant consisting of oxygen, chloride, and potassium. Because of its high oxidative capacity, ClO2 exerts antimicrobial, antiviral, and antifungal effects. However, its anticancer effects remain to be elucidated. Methodology The anticancer activity of CIO2 was assessed on DMS114 small-cell lung cancer (SCLC) cells and human umbilical vein endothelial cells (HUVEC) as control by WST-1, Annexin V, cell cycle analysis, and acridine orange staining. We for the first time investigated the possible therapeutic effects of long-term stabilized ClO2 solution (LTSCD). Results Our preliminary findings showed that LTSCD significantly inhibited the proliferation of SCLC cells (p < 0.01) with less toxicity in HUVEC cells. Additionally, LTSCD induced apoptotic cell death in SCLC cells through nuclear blebbing and vacuolar formation. However, LTSCD treatment did not induce cell cycle arrest in both cell lines. Conclusions LTSCD can be a therapeutic potential for the treatment of SCLC. However, further investigations are required to assess the LTSCD-induced cell death in SCLC both in vitro and in vivo.
Collapse
|
5
|
Bilir F, Chkhikvadze M, Yilmaz AY, Kose O, Arıöz DT. Prognostic value of systemic inflammation response index in patients with persistent human papilloma virus infection. Ginekol Pol 2022; 93:705-709. [PMID: 35106746 DOI: 10.5603/gp.a2021.0200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Revised: 09/02/2021] [Accepted: 09/11/2021] [Indexed: 11/25/2022] Open
Abstract
OBJECTIVES Persistent human papilloma virus (HPV) infection is a risk factor for the progression of cervical neoplasia into invasive carcinoma. Many inflammatory markers obtaining from hemogram parameters as platelets, monocytes, lymphocytes, and neutrophils or their ratios are still under investigation in recent decades, especially in the oncology era. Indeed, there have not been enough data about the relationship between these parameters and cervical cancer in the literature. Our primary aim was to investigate the possible relationship between the persistent HPV, which is one of the significant risk factors of cervical cancer, and these inflammatory markers. Further, we can add an easy follow-up parameter in women with persistent HPV infection. MATERIAL AND METHODS The study included patients between 30-65 years old, tested positive for HPV, and afterward had an HPV control test between January 2015 and June 2020. RESULTS The study included 114 HPV DNA-positive patients. The mean age was 43 (standard deviation 8.7), and 41 of them (36%) had persistent HPV, but the remaining 73 (64%) did not. The baseline neutrophil/lymphocyte ratio (NLR) value was 2.1, platelet/lymphocyte ratio (PLR) was 133, monocyte/lymphocyte ratio (MLR) was 0.28, and systemic inflammation response index (SIRI) was 0.9. All the parameters were significantly higher in the persistent HPV group compared to the non-persistent group. Patients who had 0.65 and under this had a significantly lower risk of persistent HPV. CONCLUSIONS Persistent HPV disease can be predicted with an elevated SIRI, NLR, and other hematologic parameters. So, we can closely follow up with these patients with different algorithms to prevent cervical cancer.
Collapse
Affiliation(s)
- Filiz Bilir
- Afyonkarahisar Health Science University Department of Gynecologic Oncology, Sakarya, Turkey, Turkey.
| | - Mariam Chkhikvadze
- Afyonkarahisar Health Science University Department of Gynecologic Oncology, Sakarya, Turkey, Turkey
| | - Ayşe Yalçinkaya Yilmaz
- Afyonkarahisar Health Science University Department of Gynecologic Oncology, Sakarya, Turkey, Turkey
| | - Osman Kose
- Department of Gynecologic Oncology, Sakarya Training and Research Hospital, Turkey
| | - Dagıstan Tolga Arıöz
- Afyonkarahisar Health Science University Department of Gynecologic Oncology, Sakarya, Turkey, Turkey
| |
Collapse
|
6
|
Eskiler G, Bilir C, Bilir F. The cytotoxic effects of indoleamine 2, 3-dioxygenase inhibitors on triple negative breast cancer cells upon tumor necrosis factor α stimulation. J Cancer Res Ther 2022; 19:S74-S80. [PMID: 37147986 DOI: 10.4103/jcrt.jcrt_2365_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Context Overexpressed indoleamine 2,3-dioxygenase (IDO) has been observed in many types of cancer and plays an essential role in the tumor microenvironment through immune cells function. Aims In our study, the therapeutic potentials of two different IDO inhibitors (Epacadostat [EPA] and 1-methyl-L-tryptophan [L-1MT]) in triple-negative breast cancer (TNBC) cells were assessed with and without tumor necrosis factor-α (TNF-α) stimulation. Materials and Methods The anticancer activity of EPA and L-1MT alone and in combination with TNF-α was analyzed by WST-1, annexin V, cell cycle analysis, and acridine orange/ethidium bromide staining. In addition, the relationship between IDO1 and programmed death-ligand 1 (PD-L1) expressions in TNBC cells upon treatment with IDO inhibitors was evaluated by reverse transcription-polymerase chain reaction analysis. Statistical Analysis Used SPSS 22.0 was conducted for statistical analysis. The one-way analysis of variance with Tukey's multiple comparison test was performed for multiple groups. Independent (unpaired) t -test was used for the comparison of two groups. Results EPA and L-1MT alone significantly suppressed the TNBC cell viability through the induction of apoptotic cell death and G0/G1 arrest (P < 0.05). TNF-α alone induced the overexpression of IDO1 and PD-L1 in TNBC cells compared with MCF-10A control cells. However, IDO inhibitors significantly inhibited overexpressed IDO1 mRNA levels. Furthermore, EPA alone and co-treated with TNF-α suppressed the mRNA level of PD-L1 in TNBC cells. Therefore, TNF-α stimulation enhanced the therapeutic effects of IDO inhibitors on TNBC. Conclusions Our findings showed that the efficacy of IDO inhibitors was mediated by pro-inflammatory cytokine. However, different molecular signaling pathways are associated with pro-inflammatory cytokines production, and the expression of IDO1 and PD-L1 calls for further investigations.
Collapse
|
7
|
Bilir F, Arioz DT, Vatansever N, Filiz T, Elaziz B. Hematologic parameters as a predictor of myometrial and cervical invasion in endometrial cancer. Minerva Obstet Gynecol 2021; 73:770-775. [PMID: 34905880 DOI: 10.23736/s2724-606x.21.04715-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Despite significant improvements in molecular biology for uterine cancer, we did not have specific peripheral blood biomarkers for clinical usage such as prognostic or predictive outcomes of disease in the last decade. METHODS A retrospective endometrial cancer database was collected from a tertiary gynecologic cancer center. The cohort included only endometrioid type uterine cancer. Subsequently, we investigated the relationship between preoperative hematologic parameters and pathologic findings. RESULTS In this study, 191 non-metastatic endometrial cancer (median age was 61 years, ranging from 41 to 86 years) were analyzed. Lymphocyte-to-monocyte ratio (LMR) was significantly different between the FIGO stage I and II (4.48 vs. 3.88, P=0.004). Platelet-to-lymphocyte (PLR) was significantly higher in FIGO stage III than stage I, and LMR was significantly decreased by each FIGO stage. LMR values significantly decreased with a depth of myometrial invasion. PLR and eosinophil-to-lymphocyte ratio (ELR) values were significantly higher in patients with cervical invasion compared to those without invasion, 287 vs. 144, P=0.005, 10.3 vs. 6, P=0.022, respectively. CONCLUSIONS This study revealed that low-LMR levels and high-PLR with ELR levels correlated with myometrial and cervical invasion, respectively. These findings can explain why hematologic parameters have an impact on oncologic outcomes.
Collapse
Affiliation(s)
- Filiz Bilir
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey -
| | - Dağıstan T Arioz
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Nefize Vatansever
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Tarık Filiz
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| | - Burçin Elaziz
- Department of Gynecologic Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey
| |
Collapse
|
8
|
Bilir F, Özgül E, Elaziz B, Arıöz DT. Clinical implication of preoperative psoas muscle area in endometrial cancer patients. Rev Assoc Med Bras (1992) 2021; 67:1759-1763. [PMID: 34909946 DOI: 10.1590/1806-9282.20210364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Accepted: 05/19/2021] [Indexed: 11/21/2022]
Abstract
OBJECTIVE Obesity is a significant risk factor for endometrial cancer. In contrast, sarcopenia describes a loss of the body's muscle mass that is closely related to unfavorable clinical outcomes. Even endometrial cancer patients have high rates of obesity, and they should have a significantly higher risk for undiagnosed sarcopenia or fragile muscle quality. METHODS This is a retrospective study that included an endometrial cancer database collected from a tertiary gynecologic cancer center. We investigated the relationship between preoperative psoas muscle area by magnetic resonance imaging, surgical outcomes and pathological features. RESULTS The study included 116 patients, the mean height was 160 cm (Standart deviation 7), weight was 72 kg (Standart deviation 18), and the median duration of hospitalization was 4 days (Interquartile range 2-9) in the whole study group. Sarcopenia was diagnosed in 25 (21.6%) patients, according to the magnetic resonance imaging findings. Three (6.5%) obese patients had sarcopenia, but it was 31.4% in nonobese patients (p=0.026). The median duration of hospitalization was five days (3-9 days) in the sarcopenia group, and it was four days (2-7 days) in the non-sarcopenia group. CONCLUSION Sarcopenic patients did not have increased surgical complication rates following uterine cancer surgery. We should be aware of hospitalization duration in those patients, and sarcopenic counterparts necessitate longer follow-up after the surgery.
Collapse
Affiliation(s)
- Filiz Bilir
- Afyonkarahisar Health Science University, Department of Gynecologic Oncology - Afyonkarahisar, Turkey
| | - Esra Özgül
- Afyonkarahisar Health Science University, Department of Radiology - Afyonkarahisar, Turkey
| | - Burçin Elaziz
- Afyonkarahisar Health Science University, Department of Gynecologic Oncology - Afyonkarahisar, Turkey
| | - Dağıstan Tolga Arıöz
- Afyonkarahisar Health Science University, Department of Gynecologic Oncology - Afyonkarahisar, Turkey
| |
Collapse
|
9
|
Bilir F, Akdemir R, Bilir C. Some, but not all of the premenstrual syndrome symptoms affect the medical exam scores in medical students. Pak J Med Sci 2021; 37:1190-1195. [PMID: 34290806 PMCID: PMC8281196 DOI: 10.12669/pjms.37.4.3931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 03/01/2021] [Accepted: 03/19/2021] [Indexed: 11/15/2022] Open
Abstract
Objectives: This research aims to identify the effects of premenstrual syndrome (PMS) symptoms on the school exam scores in medical students. Methods: This cross-sectional study was designed at Sakarya University School of Medicine The study included medical students who were in the first, second, and third year of class. In this study, there were 193 male and 100 female students. The study investigated how PMS symptoms affected medical student’s exam scores and school success. All exam scores were recorded during the two-consecutive semester so duration of study was one year Results: There were 100 female students, and they had five different committee exams for one year. Female student’s exam scores were significantly higher for four committees and an average score of all year. The mean age of female students was 19.9 ±1.5. Acne, nausea/vomiting, sleeping, abdominal bloating, and prurience change had significantly different exam scores compared to the group without these symptoms. Students with acne had substantially higher exam scores than without acne; inversely, the other four symptoms negatively affected exam scores. Conclusion: Some of the PMS symptoms can be more annoying and should change the quality of life more than the other symptoms, so we should define these symptoms to improve our student’s quality of life and school success.
Collapse
Affiliation(s)
- Filiz Bilir
- Filiz Bilir, Department of Medical Education, Sakarya University School of Medicine, Sakarya, Turkey
| | - Ramazan Akdemir
- Ramazan Akdemir, Department of Cardiology and Medical Education, Sakarya University School of Medicine, Sakarya, Turkey
| | - Cemil Bilir
- Cemil Bilir, Department of Internal Medicine, Sakarya University School of Medicine, Sakarya, Turkey
| |
Collapse
|
10
|
Dursun P, Dervisoglu H, Daggez M, Turan T, Kiliç F, Tekin ÖM, Üreyen I, Toptaş T, Demirayak G, Önder AB, Çelik Ç, Bayramoğlu D, Guzel AB, Arioz DT, Bilir F, Ozdemir IA, Tasci T, Karalok A, Karateke A. Performing gynecologic cancer surgery during the COVID-19 pandemic in Turkey: A multicenter retrospective observational study. Int J Gynaecol Obstet 2020; 151:33-38. [PMID: 32623717 PMCID: PMC9087698 DOI: 10.1002/ijgo.13296] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 06/16/2020] [Accepted: 06/29/2020] [Indexed: 12/23/2022]
Abstract
Objective To report the perioperative outcomes of 200 patients with gynecologic cancer who underwent surgery during the Novel Coronavirus Disease (COVID‐19) pandemic and the safety of surgical approach. Methods Data of patients operated between March 10 and May 20, 2020, were collected retrospectively. Data were statistically analyzed using IBM Statistical Package for the Social Sciences (SPSS) Statistics for Windows v. SP21.0. Results Data of 200 patients were included. Their mean age was 56 years. Of the patients, 54% (n=108), 27.5% (n=55), 12.5% (n=25), and 2% (n=4) were diagnosed as having endometrial, ovarian, cervical, and vulvar cancer, respectively. Of them, 98% underwent non‐emergent surgery. A minimally invasive surgical approach was used in 18%. Stage 1 cancer was found in 68% of patients. Surgeons reported COVID‐related changes in 10% of the cases. The rate of postoperative complications was 12%. Only two patients had cough and suspected pneumonic lesions on thoracic computed tomography postoperatively, but neither was positive for COVID‐19 on polymerase chain reaction testing. Conclusion Based on the present findings, it is thought that gynecologic cancer surgery should continue during the COVID‐19 pandemic while adhering to the measures. Postponement or non‐surgical management should only be considered in patients with documented infection. Gynecologic cancer surgery should continue during the COVID‐19 pandemic while adhering to measures. Only 1% of patients developed COVID‐19‐related symptoms during the postoperative follow‐up period. Gynecologic cancer surgery should continue during the COVID‐19 pandemic while adhering to measures. Only 1% of patients developed COVID‐19‐related symptoms during the postoperative follow‐up period.
Collapse
Affiliation(s)
| | - Haluk Dervisoglu
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Dr. Abdurrahman Yurtaslan Ankara Oncological Education and Research Hospital, Ankara, Turkey
| | - Mine Daggez
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Erciyes University Faculty of Medicine, Kayseri, Turkey
| | - Taner Turan
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Ankara City Hospital, Ankara, Turkey
| | - Fatih Kiliç
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Ankara City Hospital, Ankara, Turkey
| | - Özlem M Tekin
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Ankara City Hospital, Ankara, Turkey
| | - Işin Üreyen
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, University of Health Sciences Antalya Education and Research Hospital, Antalya, Turkey
| | - Tayfun Toptaş
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, University of Health Sciences Antalya Education and Research Hospital, Antalya, Turkey
| | - Gökhan Demirayak
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Bakirkoy Dr. Sadi Konuk Training & Research Hospital, Istanbul, Turkey
| | - Ayşe B Önder
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Bakirkoy Dr. Sadi Konuk Training & Research Hospital, Istanbul, Turkey
| | - Çetin Çelik
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Selcuk University Faculty of Medicine, Konya, Turkey
| | - Denizhan Bayramoğlu
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Selcuk University Faculty of Medicine, Konya, Turkey
| | - Ahmet B Guzel
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Cukurova University Faculty of Medicine, Adana, Turkey
| | - Dagistan T Arioz
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Afyonkarahisar Health Sciences University Medical School, Afyonkarahisar, Turkey
| | - Filiz Bilir
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Afyonkarahisar Health Sciences University Medical School, Afyonkarahisar, Turkey
| | - Isa A Ozdemir
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Medipol University, Istanbul, Turkey
| | - Tolga Tasci
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Bahçeşehir University Medical Park Goztepe Hospital, Istanbul, Turkey
| | - Alper Karalok
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Liv Hospital Ulus, Istanbul, Turkey
| | - Ateş Karateke
- Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Medeniyet University, Istanbul, Turkey
| |
Collapse
|